Abstract
Dalbavancin is a lipoglycopeptide antibiotic with a prolonged half-life. A phase 1 study assessed dalbavancin levels in epithelial lining fluid (ELF) in 35 healthy adults using ELF bronchial microsampling up to 168 h after administration of 1,500 mg dalbavancin. The penetration of dalbavancin into ELF was 36%. ELF levels of dalbavancin exceeded the MIC90s of Streptococcus pneumoniae and Staphylococcus aureus for ≥7 days.
Keywords:
dalbavancin; lung epithelial lining fluid; pharmacodynamics; pharmacokinetics; pneumonia.
Copyright © 2019 Rappo et al.
Publication types
-
Clinical Trial, Phase I
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / analysis
-
Anti-Bacterial Agents / blood
-
Anti-Bacterial Agents / pharmacokinetics*
-
Humans
-
Infusions, Intravenous
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Pneumonia, Bacterial / drug therapy
-
Pneumonia, Pneumococcal / drug therapy
-
Pneumonia, Staphylococcal / drug therapy
-
Respiratory Mucosa / chemistry*
-
Staphylococcus aureus / drug effects
-
Streptococcus pneumoniae / drug effects
-
Teicoplanin / administration & dosage
-
Teicoplanin / analogs & derivatives*
-
Teicoplanin / analysis
-
Teicoplanin / blood
-
Teicoplanin / pharmacokinetics
-
Young Adult
Substances
-
Anti-Bacterial Agents
-
Teicoplanin
-
dalbavancin